Boundless Bio And Serapha Bio Announce Merger And $230 Million Private Placement; Stock Up

Boundless Bio (BOLD) and privately held Serapha Bio have entered into a definitive all-stock merger agreement. The deal combines two biotechnology companies, including Serapha’s in vivo base-editing therapy program for Alpha-1 Antitrypsin Deficiency (AATD). The announcement is modestly positive for Boundless Bio as a strategic combination, though no transaction value or closing timeline was disclosed.

Analysis

Boundless Bio (BOLD) and privately held Serapha Bio have entered into a definitive all-stock merger agreement. The deal combines two biotechnology companies, including Serapha’s in vivo base-editing therapy program for Alpha-1 Antitrypsin Deficiency (AATD). The announcement is modestly positive for Boundless Bio as a strategic combination, though no transaction value or closing timeline was disclosed.